Clinical trial NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Official title: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Obesity
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2022-10-05
Enrollment: 3400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.

Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.


Eligibility criteria: Inclusion Criteria:

* Male or female
* Age above or equal to 18 years at the time of signing informed consent
* Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or b) BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

Exclusion Criteria:

- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus

Primary outcomes:
measure: CagriSema versus placebo: Relative change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
Secondary outcomes:
measure: CagriSema versus placebo: Achievement of >= 20% weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Achievement of >= 25% weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Achievement of >= 30% weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Relative change in body weight
timeFrame: From baseline (week 0) to week 8
measure: CagriSema versus placebo: Relative change in body weight
timeFrame: From baseline (week 0) to week 20
measure: CagriSema versus placebo: Change in waist circumference
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in systolic blood pressure (SBP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in HbA1c
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L).
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in FPG (mg/dL)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in fasting serum insulin
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in total cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in Triglycerides
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Ratio to baseline in Free fatty acids
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Change in waist circumference
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Change in SBP
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Relative change in body weight (Measured in percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%))
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in Control of Eating (COEQ): Craving Control Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in COEQ: Craving for Savoury food score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in COEQ: Hunger score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in COEQ: Craving for Sweets Score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in COEQ: Positive Mood score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Change in COEQ: Satiety score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Number of Treatment Emergent Adverse Events (TEAEs)
timeFrame: From baseline (week 0) to end of study-main part (week 75)
measure: Number of Treatment Emergent Serious adverse events (TESAEs)
timeFrame: From baseline (week 0) to end of study-main part (week 75)
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Univ of Alabama Birmingham
state: Alabama
city: Los Angeles
country: United States
facility: Velocity Clin Res Los Angeles
state: California
city: Los Angeles
country: United States
facility: Velocity Clin Res Wstlke
state: California
city: Aurora
country: United States
facility: Univ of Colorado at Denver
state: Colorado
city: Golden
country: United States
facility: New West Physicians,Inc.
state: Colorado
city: Fleming Island
country: United States
facility: Northeast Research Institute
state: Florida
city: Miramar
country: United States
facility: South Broward Research LLC
state: Florida
city: Orlando
country: United States
facility: Clinical Neuroscience Solution
state: Florida
city: Orlando
country: United States
facility: Florida Inst For Clin Res
state: Florida
city: Plantation
country: United States
facility: Clinical Trial Res Assoc,Inc
state: Florida
city: Conyers
country: United States
facility: Hope Clin Res & Wellness
state: Georgia
city: Honolulu
country: United States
facility: East West Med Res Inst
state: Hawaii
city: Chicago
country: United States
facility: Great Lakes Clinical Trials
state: Illinois
city: Skokie
country: United States
facility: Endeavor Health
state: Illinois
city: Skokie
country: United States
facility: Evanston Premier Hlthcr Res
state: Illinois
city: Indianapolis
country: United States
facility: Midwest Inst For Clin Res
state: Indiana
city: Buckley
country: United States
facility: Northern Pines Hlth Ctr, PC
state: Michigan
city: Saint Peters
country: United States
facility: StudyMetrix Research LLC
state: Missouri
city: New York
country: United States
facility: Comprehensive Weight Ctrl Prog
state: New York
city: Vestal
country: United States
facility: Velocity Clinical Res. Inc Vestal
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
city: Greensboro
country: United States
facility: Medication Mgmnt, LLC_Grnsboro
state: North Carolina
city: Greensboro
country: United States
facility: PharmQuest Life Sciences LLC
state: North Carolina
city: Raleigh
country: United States
facility: Accellacare_NC
state: North Carolina
city: Wilmington
country: United States
facility: Accellacare
state: North Carolina
city: Wadsworth
country: United States
facility: New Venture Medical Research
state: Ohio
city: Norman
country: United States
facility: Lynn Institute of Norman
state: Oklahoma
city: Philadelphia
country: United States
facility: The University of Penn Center
state: Pennsylvania
city: Cumberland
country: United States
facility: Clinical Res Collaborative
state: Rhode Island
city: Charleston
country: United States
facility: Medical Uni of SC Charleston
state: South Carolina
city: North Charleston
country: United States
facility: Coastal Carolina Res Ctr
state: South Carolina
city: Simpsonville
country: United States
facility: Hillcrest Clinical Research
state: South Carolina
city: Spartanburg
country: United States
facility: Spartanburg Medical Research
state: South Carolina
city: Bristol
country: United States
facility: Holston Medical Group_Bristol
state: Tennessee
city: Kingsport
country: United States
facility: Holston Medical Group
state: Tennessee
city: Dallas
country: United States
facility: Baylr Sctt White Rs Inst, Endo
state: Texas
city: Dallas
country: United States
facility: Velocity Clinical Res-Dallas
state: Texas
city: Dallas
country: United States
facility: UT Southwestern Med Cntr
state: Texas
city: Longview
country: United States
facility: DCOL Ctr for Clin Res
state: Texas
city: Arlington
country: United States
facility: Washington Cntr Weight Mgmt
state: Virginia
city: Newport News
country: United States
facility: Health Res of Hampton Roads
state: Virginia
city: Winchester
country: United States
facility: Selma Medical Associates
state: Virginia
city: Olympia
country: United States
facility: Capital Clin Res Ctr,LLC
state: Washington
city: Renton
country: United States
facility: Rainier Clin Res Ctr Inc
state: Washington
city: Santa Rosa
country: Argentina
facility: Fundación CESIM
state: La Pampa
city: Caba
country: Argentina
facility: Centro de Investigación Clínica
city: Caba
country: Argentina
facility: Centro Médico Viamonte SRL
city: Ciudad de Buenos Aires
country: Argentina
facility: Instituto Centenario
city: Santiago del Estero
country: Argentina
facility: Sanatorio Norte
city: Brookvale
country: Australia
facility: Northern Beaches Clinical Research
state: New South Wales
city: Darlinghurst
country: Australia
facility: Momentum Clinical Research Darlinghurst
state: New South Wales
city: Kotara
country: Australia
facility: Novatrials
state: New South Wales
city: Taringa
country: Australia
facility: Momentum Clinical Research
state: Queensland
city: Bonheiden
country: Belgium
facility: Imeldaziekenhuis - Bonheiden - Department of Endocrinology
city: Boussu
country: Belgium
facility: CHR Mons-Hainaut - Site Warquignies
city: Boussu
country: Belgium
facility: CHU Helora - Site Warquignies
city: Bruxelles
country: Belgium
facility: Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
city: Edegem
country: Belgium
facility: UZ Antwerpen - UZA - Department of Endocrinology
city: Edegem
country: Belgium
facility: UZA - UZ Antwerpen - Department of Endocrinology
city: Gent
country: Belgium
facility: UZ Gent - Endocrinologie
city: Leuven
country: Belgium
facility: UZ Leuven - Endocrinology
city: Dupnitsa
country: Bulgaria
facility: Medical centre Asclepius
state: Kyustendil
city: Blagoevgrad
country: Bulgaria
facility: "Multiprofile hospital for active treatment Puls" AD
city: Montana
country: Bulgaria
facility: "Outpatient clinic for Individual Practice for Specialized Outpatient Medical Care - Endocrinology NT" EOOD
city: Pleven
country: Bulgaria
facility: OCSOMCE - Dr. Albena Dinkova EOOD
city: Plovdiv
country: Bulgaria
facility: "Diagnostic - consulting center iztok" EOOD
city: Ruse
country: Bulgaria
facility: ASOMCEM - IP - Dr. Antoanela Slavcheva
city: Smolyan
country: Bulgaria
facility: "Nader Yabrudi - ASMPVBE Individual practice"
city: Sofia
country: Bulgaria
facility: UMHAT "Aleksandrovska"
city: Sofia
country: Bulgaria
facility: USHATE "Acad. Ivan Penchev" First Clinic of Endocrinology
city: Sofia
country: Bulgaria
facility: USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
city: Sofia
country: Bulgaria
facility: "Diagnostic - consulting center 18 - Sofia" EOOD
city: Sofia
country: Bulgaria
facility: "UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Clinic of endocrinology and metabolic disease for metabolic disorders treatment
city: Sofia
country: Bulgaria
facility: "DCC XX - Sofia" EOOD, Endocrinology Consulting Room
city: Varna
country: Bulgaria
facility: AIPSMC Dr. Artin Magardichyan EOOD
city: Yambol
country: Bulgaria
facility: Medical center Berbatov
city: Edmonton
country: Canada
facility: C-endo Diab & Endo Clinic
state: Alberta
city: Sherwood Park
country: Canada
facility: Synergy Wellness Clinic
state: Alberta
city: Surrey
country: Canada
facility: Ocean West Research Clinic
state: British Columbia
city: Victoria
country: Canada
facility: Dr. M.B. Jones Inc
state: British Columbia
city: Moncton
country: Canada
facility: G.A. Research Associates Ltd.
state: New Brunswick
city: Halifax
country: Canada
facility: Nova Scotia Hlth Halifax
state: Nova Scotia
city: Hamilton
country: Canada
facility: Premier Clinical Trial Research Network (PCTRN)
state: Ontario
city: Aarhus N
country: Denmark
facility: Aarhus Universitetshospital Diabetes og Hormonsygdomme
city: Esbjerg
country: Denmark
facility: Sydvestjysk Sygehus Esbjerg
city: Hellerup
country: Denmark
facility: Center for Klinisk Metabolisk Forskning
city: Hvidovre
country: Denmark
facility: Hvidovre Hospital Endokrinologisk forsknings afsnit 159
city: Køge
country: Denmark
facility: Sjællands Universitetshospital
city: Helsinki
country: Finland
facility: HUS Clinical Research Biomedicum 2U
city: Kuopio
country: Finland
facility: Health Step Finland Oy
city: Oulu
country: Finland
facility: OYS Sisätautien tutkimusyksikkö
city: Turku
country: Finland
facility: Turku University Hospital
city: Paris
country: France
facility: Aphp-Hopital La Pitie Salpetriere-3
city: Pierre-Benite
country: France
facility: Hospices Civils de Lyon-Hopital Lyon Sud-1
city: Saint Herblain
country: France
facility: Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
city: Strasbourg cedex 2
country: France
facility: Les Hopitaux Universitaires de Strasbourg-Hopital de Hautepierre-1
city: Venissieux
country: France
facility: Centre de Recherche Clinique Portes Du Sud
city: Bad Mergentheim
country: Germany
facility: Diabetespraxis Mergentheim
city: Elsterwerda
country: Germany
facility: Zentrum fuer klinische Studien Suedbrandenburg GmbH
city: Essen
country: Germany
facility: InnoDiab Forschung GmbH
city: Hamburg
country: Germany
facility: Wendisch/Dahl Hamburg (DZHW)
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig - Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie
city: Leipzig
country: Germany
facility: AmBeNet GmbH
city: Münster
country: Germany
facility: Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
city: Stuttgart
country: Germany
facility: MZM Praxis Drs. Erlinger
city: Wangen
country: Germany
facility: Zentrum für klinische Studien Allgäu Oberschwaben
city: Surat
country: India
facility: Nirmal Hospital Pvt. Ltd.
state: Gujarat
city: Kozhikode
country: India
facility: Government Medical College, Kozhikode
state: Kerala
city: Mumbai
country: India
facility: Sir H. N. Reliance Foundation Hospital and Research Centre
state: Maharashtra
city: Mumbai
country: India
facility: Wockhardt Hospital, Mumbai Central
state: Maharashtra
city: Pune
country: India
facility: Grant Medical Foundation Ruby Hall Clinic
state: Maharashtra
city: Pune
country: India
facility: Deenanath Mangeshkar Hospital & Research Centre
state: Maharashtra
city: Pune
country: India
facility: Sahyadri Super Speciality Hospital
state: Maharashtra
city: Pune
country: India
facility: chelleram Diabetes Institute
state: Maharashtra
city: Delhi
country: India
facility: Maulana Azad Medical College
state: New Delhi
city: Jaipur
country: India
facility: SMS Medical College & Hospital
state: Rajasthan
city: Jaipur
country: India
facility: Eternal Heart Care Centre
state: Rajasthan
city: Vellore
country: India
facility: Christian Medical College Hospital, Vellore
state: Tamil Nadu
city: Delhi
country: India
facility: All India Institute of Medical Sciences_New Dehli
city: Hyderabad
country: India
facility: Osmania General Hospital
city: Catanzaro
country: Italy
facility: Azienda Ospedaliero-Universitaria Renato Dulbecco
state: Cz
city: San Donato Milanese (MI)
country: Italy
facility: Policlinico San Donato
state: Lombardia
city: Roma
country: Italy
facility: Pol. Uni. Campus Biomedico
state: RM
city: Siena
country: Italy
facility: Azienda Ospedaliera Universitaria Senese
state: SI
city: Bologna
country: Italy
facility: A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura
city: Catania
country: Italy
facility: ARNAS (Azienda Ospedaliera di Rilievo Nazionale di Alta Specializzazione) Ospedale Garibaldi
city: Padova
country: Italy
facility: Azienda Ospedaliera di Padova Clin.Med.3
city: Roma
country: Italy
facility: Policlinico Universitario Tor Vergata
city: Roma
country: Italy
facility: Azienda Ospedaliera Universitaria Policlinico Umberto I
city: Sapporo city
country: Japan
facility: Iryouhoujinsyadan Shoureikan Shinsapporo Seiryou Hospital
state: Hokkaido
city: Suita-shi
country: Japan
facility: OCROM Clinic
state: Osaka
city: Aichi
country: Japan
facility: TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
city: Chiba-shi, Chiba
country: Japan
facility: Chiba University Hospital_Diabetes, Metabolism and Endocrinology
city: Gunma
country: Japan
facility: Kawada Clinic
city: Kanagawa
country: Japan
facility: Motomachi Takatsuka Naika Clinic_Internal Medicine
city: Osaka
country: Japan
facility: Osaka NISHI-UMEDA Clinic
city: Saitama
country: Japan
facility: Asano Clinic
city: Sendai-shi, Miyagi
country: Japan
facility: Shinden Higashi Clinic
city: Tokyo
country: Japan
facility: Tokyo-Eki Center-building Clinic
city: Tokyo
country: Japan
facility: Fukuwa Clinic
city: Tokyo
country: Japan
facility: Miho Clinic
city: Tokyo
country: Japan
facility: ToCROM Clinic
city: Tokyo
country: Japan
facility: Higashi-shinjuku clinic
city: Bucheon-si
country: Korea, Republic of
facility: The catholic university of Korea, Bucheon St.Mary's Hospital
state: Gyeonggi-do
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Hospital
city: Daejeon
country: Korea, Republic of
facility: Daejeon Eulji Medical Center, Eulji University
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Seongnam-si, Gyeonggi-do
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Yangsan
country: Korea, Republic of
facility: Pusan National University Yangsan Hospital
city: Guadalajara
country: Mexico
facility: Arechavaleta Granell María del Rosario
state: Jalisco
city: Monterrey
country: Mexico
facility: Cardiolink Clin Trials S.C.
state: Nuevo Leon
city: Aguascalientes
country: Mexico
facility: Centro de Investigación Cardiometabólica de Aguascalientes
city: Amsterdam
country: Netherlands
facility: Academisch Medisch Centrum
city: Arnhem
country: Netherlands
facility: Rijnstate Ziekenhuis
city: Hoofddorp
country: Netherlands
facility: Spaarne Gasthuis_Hoofddorp
city: Roosendaal
country: Netherlands
facility: Bravis Ziekenhuis
city: Zwijndrecht
country: Netherlands
facility: Albert Schweitzer Ziekenhuis, locatie Zwijndrecht
city: Legnica
country: Poland
facility: Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
state: Dolnośląskie
city: Bydgoszcz
country: Poland
facility: 50BIO.COM Sp. z o.o.
state: Kujawsko-Pomorskie Voivodeship
city: Bygdoszcz
country: Poland
facility: Gierach-Med
state: Kuyavian-Pomeranian Voivodeship
city: Lublin
country: Poland
facility: Terpa Sp. z o.o. Sp. k.
state: Lubelskie Voivodeship
city: Warszawa
country: Poland
facility: Instytut Diabetologii Sp. z o.o.
state: Mazovian Voivodeship
city: Warszawa
country: Poland
facility: Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego
state: Mazowieckie
city: Krakow
country: Poland
facility: Centrum Medyczne Plejady
state: Małopolskie
city: Bialystok
country: Poland
facility: Uniwersytecki Szpital Kliniczny w Bialymstoku
state: Podlaskie Voivodeship
city: Bialystok
country: Poland
facility: Gabinet Leczenia Otylosci i Chorob Dietozaleznych
state: Podlaskie Voivodeship
city: Bialystok
country: Poland
facility: NZOZ Vita-Diabetica Malgorzata Buraczyk
state: Podlaskie Voivodeship
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
state: Pomorskie
city: Katowice
country: Poland
facility: Centrum Medyczne Salvia
state: Slaskie Voivodeship
city: Elblag
country: Poland
facility: Klinika Bellamed
state: Warmińsko-Mazurskie
city: Poznan
country: Poland
facility: Centrum Zdrowia Metabolicznego
state: Wielkopolskie Voivodeship
city: Poznań
country: Poland
facility: Centrum Ginekologii, Położnictwa i Leczenia Niepłodności
state: Wielkopolskie Voivodeship
city: Legnica
country: Poland
facility: Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
city: Warszawa
country: Poland
facility: Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego
city: Novi Sad
country: Serbia
facility: Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
state: Vojvodina
city: Belgrade
country: Serbia
facility: Endocrinology, Diabetes and Metabolism Diseases Clinic
city: Belgrade
country: Serbia
facility: Clinical Hospital Center Bezanijska Kosa
city: Novi Sad
country: Serbia
facility: Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
city: Johannesburg
country: South Africa
facility: East Rand Physicians
state: Gauteng
city: Johannesburg
country: South Africa
facility: Dr R Dulabh
state: Gauteng
city: Lenasia
country: South Africa
facility: Dr Moosa's Rooms
state: Gauteng
city: Midrand
country: South Africa
facility: Shop#1 Health Emporium
state: Gauteng
city: Pretoria
country: South Africa
facility: Botho ke Bontle Health Services
state: Gauteng
city: Durban
country: South Africa
facility: Dr Vawda's site
state: KwaZulu-Natal
city: Durban
country: South Africa
facility: Dr J Reddy
state: KwaZulu-Natal
city: Brits
country: South Africa
facility: Armansis Medical Centre
state: North West
city: Pamplona
country: Spain
facility: Clinica Universitaria de Navarra
state: Navarra
city: Barcelona
country: Spain
facility: Hospital Clinic i Provincial
city: Castilleja Dela Cuesta Sevilla
country: Spain
facility: Hospital Vithas Sevilla
city: León
country: Spain
facility: Hospital de León
city: Madrid
country: Spain
facility: Hospital Gregorio Marañón
city: Sevilla
country: Spain
facility: Clínica Nuevas Tecnologías en Diabetes y Endocrinología
city: Sevilla
country: Spain
facility: Hospital Infanta Luisa
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Ankara
country: Turkey
facility: Baskent University Ankara Hospital
state: Cankaya
city: Adana
country: Turkey
facility: T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
city: Adana
country: Turkey
facility: Baskent Universitesi Adana
city: Ankara
country: Turkey
facility: Ankara Sehir Hastanesi Dahiliye Klinigi
city: Antalya
country: Turkey
facility: Akdeniz University Tip Fakultesi Hastanesi
city: Hatay
country: Turkey
facility: Hatay Mustafa Kemal Universitesi Saglik Uygulama ve Arastirm
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji
city: Istanbul
country: Turkey
facility: TC SB Ist.İl Sag.Müd.Prof.Dr.Cemil Tascioglu Sehir Hastanesi
city: Istanbul
country: Turkey
facility: Haydarpasa Numune Egitim Arastirma Hastanesi Endokrinoloji
city: Istanbul
country: Turkey
facility: T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
city: Sivas
country: Turkey
facility: Sivas Cumhuriyet Univesity Endocrinology Department
city: Blackpool
country: United Kingdom
facility: Layton Medical Centre
city: Bristol
country: United Kingdom
facility: Southmead Hospital
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital_Cambridge
city: Chester
country: United Kingdom
facility: Countess Of Chester NHS Foundation Trust
city: Chippenham
country: United Kingdom
facility: Hathaway Medical Centre
city: Coventry
country: United Kingdom
facility: WISDEM Centre
city: Liverpool
country: United Kingdom
facility: University Hospital Aintree
city: London
country: United Kingdom
facility: Guys Hospital
city: London
country: United Kingdom
facility: Imperial College London
city: London
country: United Kingdom
facility: UCL - Obesity
city: Orpington
country: United Kingdom
facility: Princess Royal University Hospital
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: